Axsome Therapeutics (AXSM) is up about 3.25% in Monday trading as investors and short-term traders crowd into a major binary catalyst later this week: the FDA’s April 30, 2026 target action date for the company’s supplemental NDA seeking approval of AXS-05 (marketed as Auvelity) for agitation associated with Alzheimer’s disease. With the decision window now days away, the move looks primarily catalyst-driven positioning rather than a reaction to new company-issued results today.

The April 30 PDUFA date is the key near-term driver because it would expand Auvelity/AXS-05 beyond major depressive disorder into a second indication tied to a large, underserved patient population. Heading into the decision, investor focus is on whether the FDA is satisfied with the resubmission package after prior regulatory friction tied to manufacturing, since the current setup is widely viewed as a label-expansion opportunity that could meaningfully raise the product’s long-term revenue trajectory if approved.

Beyond the FDA event, AXSM has another scheduled headline catalyst close behind: the company is set to report Q1 2026 results before the market opens on May 4, 2026. That proximity can amplify volatility, because the stock may need to digest both regulatory outcome risk and near-term commercial execution metrics (Auvelity and Sunosi demand trends, gross-to-net dynamics, and operating expense trajectory) within the same trading week.